Abstract 187P
Background
The recurrence rate of hepatocellular carcinoma (HCC) remains high and multinodular HCC is a well-defined high-risk factor. This trial is to evaluate the safety and efficacy of cadonilimab plus HAIC as a neoadjuvant management for the resectable multinodular HCC with CNLC stage Ⅰb/Ⅱa.
Methods
In this ongoing single-center, phase 2, open label, prospective cohort clinical trial, eligible patients (pts) were randomly assigned (1:1:1) to 3 arms and receive neoadjuvant therapy: (A) 2 cycles of cadonilimab (6mg/kg Q2W); (B) once HAIC with FOLFOX regimen followed by 2 cycles of cadonilimab; (C) once FOLFOX-HAIC. Pts receive scheduled surgery on day 21-28 and adjuvant HAIC one month after surgery. Primary endpoints were major pathologic response (MPR defined as ≤50% residual living tumor) and 1-year RFS rate. Secondary endpoints included ORR, DCR and TRAEs.
Results
From January 4 to August 20, 2023, 18 pts were enrolled and 16 pts have received scheming hepatectomy (5 pts in Arm A, 9 pts in Arm B, 2 pt in Arm C). Remarkably, almost all (8/9) pts in Arm B achieved MPR and some pts demonstrated focal heterogeneity—one lesion achieved pathologic complete response, while another got non-/partial response. No obvious tumor necrosis in Arm A and C, but the inflammatory infiltrating and fibrosis area seemed to increase in some HCC lesions. 3 pts in Arm B (3/9) achieved PR and DCR was 100% per RECIST 1.1. The most common TRAEs in Arm B and C were increased ALT, AST (Grade 1-3) and bilirubin (Grade 1), which mainly resulted from HAIC and can be improved by routine liver protection treatment. Main TRAEs observed in Arm A was increased AST (Grade 3). Two pts in Arm A and B delayed scheduled surgery for 3 weeks due to increased ALT/AST. One pt experienced postoperative controllable pneumonia which may relate to novel coronavirus (2019-nCoV) and cadonilimab. One pt experienced postoperative severe but curable bacterial hepatic abscess related to bilioenteric anastomosis and diabetes mellitus.
Conclusions
This study preliminarily demonstrated that neoadjuvant cadonilimab plus FOLFOX-HAIC had a promising antitumor activity and a manageable safety for the resectable multinodular HCC.
Clinical trial identification
ChiCTR2200067161; Chinese Clinical Trial Registry; 2022-12-28.
Editorial acknowledgement
The authors acknowledge to Akeso Biopharma Ltd. for their drugs and writing supports.
Legal entity responsible for the study
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University.
Funding
Akeso Biopharma Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract